The efficacy and safety of endostar combined with taxane-based regimens for HER-2-negative metastatic breast cancer patients.

Oncotarget · 2016 · PMC5058773 · PMID 27129172

Europe PMC DOI

hedged sentence

0.0580

closest p · 1.2× alpha

0.0580

boldest claim

The sentences

showed a trendP=0.058so close (0.05 < p ≤ 0.1)

The patients not pretreated with taxanes showed a trend of longer median PFS compared to those pretreated with taxanes (P=0.058).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.